Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Quality of Life Research
Gepubliceerd in:

11-05-2021

Comparison of EQ-5D-3L and metabolic components between patients with hyperhidrosis and the general population: a propensity score matching analysis

Auteurs: Yea-Chan Lee, Young Kyung You, Jun Hyuk Lee, Duk Hwan Moon, Sungsoo Lee, Soyoung Jeon, Hye Sun Lee, Ji-Won Lee

Gepubliceerd in: Quality of Life Research | Uitgave 9/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

It is important to understand the characteristics of patients with hyperhidrosis, which are different from the general population, for treating hyperhidrosis. Sympathetic overactivity, which might play an important role in hyperhidrosis, can contribute to metabolic diseases and the decreased quality of life (QoL). We compared the metabolic components and health-related QoL between patients with hyperhidrosis and the general population.

Methods

We conducted a case-control study and compared the characteristics of the patients (N = 196) with hyperhidrosis and propensity score-matched controls (N = 196) selected from the Korean National Health and Nutrition Examination Survey. Metabolic components and EQ-5D-3L (EQ-5D) index were compared using a two-way mixed analysis of covariance after adjusting for confounders.

Results

Patients with hyperhidrosis had significantly higher waist circumference (estimated mean values ± SD for patients and the control group, 85.5  ±  10.8 cm vs 81.3  ±  10.3 cm, p < 0.001), blood pressure (SBP, 121.1  ±  16.9 vs 111.7  ±  10.3, p < 0.001 AND DBP, 77.5  ±  12.8 vs 73.6  ±  8.6, p < 0.001, respectively), fasting glucose (97.1  ±  11.3 vs 91.5  ±  9.2, p < 0.001), and the number of components of metabolic syndrome (1.4  ±  1.3 vs 1.0  ±  1.2, p = 0.002), and significantly lower estimated glomerular filtration rate (144.3  ±  53.2 vs 158.3  ±  55.7, p = 0.002) and EQ-5D values (estimated mean values (standard error) for patients and the control group, 0.92 (0.01) vs 0.97 (0.01), p < 0.001) compared to the control group after adjustment.

Conclusion

The patients with hyperhidrosis had more central obesity and unfavorable metabolic parameters and a lower EQ-5D index compared with the general population, emphasizing clinical importance of hyperhidrosis to be cured in aspect of metabolic components as well as patients’ QOL.
vorige artikel The predictive ability of EQ-5D-3L compared to the LACE index and its association with 30-day post-hospitalization outcomes
volgende artikel Association between knee symptoms, change in knee symptoms over 6–9 years, and SF-6D health state utility among middle-aged Australians
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Park, J.-M., Moon, D. H., Lee, H. S., Park, J.-Y., Lee, J.-W., & Lee, S. (2019). Hyperhidrosis, endoscopic thoracic sympathectomy, and cardiovascular outcomes: A cohort study based on the Korean health insurance review and assessment service database. International Journal of Environmental Research and Public Health, 16(20), 3925.PubMedCentralCrossRef
2.
Henning, M., Pedersen, O., & Jemec, G. (2019). Genetic disposition to primary hyperhidrosis: A review of literature. Archives of Dermatological Research, 311(10), 1–6.CrossRef
3.
Lai, F.-C., Tu, Y.-R., Li, Y.-P., Li, X., Lin, M., Chen, J.-F., et al. (2015). Nation Wide epidemiological survey of primary palmar hyperhidrosis in the People’s Republic of China. Clinical Autonomic Research, 25(2), 105–108.PubMedCrossRef
4.
Strutton, D. R., Kowalski, J. W., Glaser, D. A., & Stang, P. E. (2004). US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey. Journal of the American Academy of Dermatology, 51(2), 241–248.PubMedCrossRef
5.
Tu, Y.-R., Li, X., Lin, M., Lai, F.-C., Li, Y.-P., Chen, J.-F., et al. (2007). Epidemiological survey of primary palmar hyperhidrosis in adolescent in Fuzhou of People’s Republic of China. European Journal of Cardio-Thoracic Surgery, 31(4), 737–739.PubMedCrossRef
6.
Nawrocki, S., & Cha, J. (2019). The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options. Journal of the American Academy of Dermatology, 81(3), 669–680.PubMedCrossRef
7.
Solish, N., Bertucci, V., Dansereau, A., HONG, H. C. H., Lynde, C., Lupin, M., et al. (2007). A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: Recommendations of the Canadian hyperhidrosis advisory committee. Dermatologic Surgery, 33(8), 908–923.PubMed
8.
Solish, N., Wang, R., & Murray, C. A. (2008). Evaluating the patient presenting with hyperhidrosis. Thoracic Surgery Clinics, 18(2), 133–140.PubMedCrossRef
9.
Schlaich, M., Straznicky, N., Lambert, E., & Lambert, G. (2015). Metabolic syndrome: A sympathetic disease? The Lancet Diabetes and Endocrinology, 3(2), 148–157.PubMedCrossRef
10.
Martin, C. K., Church, T. S., Thompson, A. M., Earnest, C. P., & Blair, S. N. (2009). Exercise dose and quality of life: A randomized controlled trial. Archives of Internal Medicine, 169(3), 269–278.PubMedPubMedCentralCrossRef
11.
Wei, Y., Xu, Z.-Q.D., & Li, H. (2020). Quality of life after thoracic sympathectomy for palmar hyperhidrosis: A meta-analysis. General Thoracic and Cardiovascular Surgery, 68(6), 1–8.
12.
de Campos, J. R. M., Kauffman, P., de Campos Werebe, E., Andrade Filho, L. O., Kusniek, S., Wolosker, N., et al. (2003). Quality of life, before and after thoracic sympathectomy: Report on 378 operated patients. The Annals of Thoracic Surgery, 76(3), 886–891.PubMedCrossRef
13.
Kumagai, K., Kawase, H., & Kawanishi, M. (2005). Health-related quality of life after thoracoscopic sympathectomy for palmar hyperhidrosis. The Annals of Thoracic Surgery, 80(2), 461–466.PubMedCrossRef
14.
Sobrinho, S. S., Fiorelli, R., & Morard, M. (2017). Evaluation of the quality of life of patients with primary hyperhidrosis submitted to videothoracoscopic sympathectomy. Revista do Colegio Brasileiro de Cirurgioes, 44(4), 323–327.
15.
16.
McCaffrey, N., Kaambwa, B., Currow, D. C., & Ratcliffe, J. (2016). Health-related quality of life measured using the EQ-5D–5L: South Australian population norms. Health and Quality of Life Outcomes, 14(1), 133.PubMedPubMedCentralCrossRef
17.
Kweon, S., Kim, Y., Jang, M.-J., Kim, Y., Kim, K., Choi, S., et al. (2014). Data resource profile: The Korea national health and nutrition examination survey (KNHANES). International Journal of Epidemiology, 43(1), 69–77.PubMedPubMedCentralCrossRef
18.
Imai, E., Horio, M., Yamagata, K., Iseki, K., Hara, S., Ura, N., et al. (2008). Slower decline of glomerular filtration rate in the Japanese general population: A longitudinal 10-year follow-up study. Hypertension Research, 31(3), 433–441.PubMedCrossRef
19.
Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., et al. (2005). Diagnosis and management of the metabolic syndrome. Circulation, 112, 2735–2740.PubMedCrossRef
20.
Peralta, C. A., Kurella, M., Lo, J. C., & Chertow, G. M. (2006). The metabolic syndrome and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 15(4), 361–365.PubMedCrossRef
21.
Qiu, Y., Zhao, Q., Gu, Y., Wang, N., Yu, Y., Wang, R., et al. (2019). Association of metabolic syndrome and its components with decreased estimated glomerular filtration rate in adults. Annals of Nutrition and Metabolism, 75(3), 168–178.PubMedCrossRef
22.
Parsons, L. S. (2004). Performing a 1: N case-control match on propensity score. In: Proceedings of the 29th annual SAS user's group international conference (Vol.1, p. e11). SAS Institute.
23.
24.
25.
Shibasaki, M., & Crandall, C. G. (2010). Mechanisms and controllers of eccrine sweating in humans. Frontiers in Bioscience (Scholar edition), 2, 685.
26.
Harker, M. (2013). Psychological sweating: A systematic review focused on aetiology and cutaneous response. Skin Pharmacology and Physiology, 26(2), 92–100.PubMedCrossRef
27.
Shibasaki, M., Wilson, T. E., & Crandall, C. G. (2006). Neural control and mechanisms of eccrine sweating during heat stress and exercise. Journal of Applied Physiology, 100(5), 1692–1701.PubMedCrossRef
28.
Sowers, J. R., & Frohlich, E. D. (2004). Insulin and insulin resistance: Impact on blood pressure and cardiovascular disease. Medical Clinics, 88(1), 63–82.PubMed
29.
Iyngkaran, P., Anavekar, N., Majoni, W., & Thomas, M. C. (2013). The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes. Diabetes and Metabolism, 39(4), 290–298.PubMedCrossRef
30.
Yeung, A. C., Vekshtein, V. I., Krantz, D. S., Vita, J. A., Ryan, T. J., Jr., Ganz, P., et al. (1991). The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. New England Journal of Medicine, 325(22), 1551–1556.CrossRefPubMed
31.
Volders, P. G. (2010). Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis. Heart Rhythm, 7(12), 1900–1906.PubMedCrossRef
32.
Ben-David, J., & Zipes, D. P. (1988). Differential response to right and left ansae subclaviae stimulation of early afterdepolarizations and ventricular tachycardia induced by cesium in dogs. Circulation, 78(5), 1241–1250.PubMedCrossRef
33.
Hanich, R., Levine, J., Spear, J., & Moore, E. (1988). Autonomic modulation of ventricular arrhythmia in cesium chloride-induced long QT syndrome. Circulation, 77(5), 1149–1161.PubMedCrossRef
34.
Zoccali, C., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Benedetto, F. A., et al. (2002). Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension, 40(1), 41–46.PubMedCrossRef
35.
Canale, M. P., Manca di Villahermosa, S., Martino, G., Rovella, V., Noce, A., De Lorenzo, A., et al. (2013). Obesity-related metabolic syndrome: Mechanisms of sympathetic overactivity. International Journal of Endocrinology, 2013, 1–12.CrossRef
36.
37.
Landsberg, L. (1996). Obesity and the insulin resistance syndrome. Hypertension Research, 19(Suppl I), S51–S55.PubMedCrossRef
38.
Reaven, G. M. (2010). Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: Syndrome X revisited. Comprehensive Physiology, 1, 1169–1197.
39.
Wang, C. C. L., Goalstone, M. L., & Draznin, B. (2004). Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes, 53(11), 2735–2740.PubMedCrossRef
40.
Grassi, G. (2006). Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertension Research, 29(11), 839–847.PubMedCrossRef
41.
Alvarez, G. E., Ballard, T. P., Beske, S. D., & Davy, K. P. (2004). Subcutaneous obesity is not associated with sympathetic neural activation. American Journal of Physiology-Heart and Circulatory Physiology, 287(1), H414–H418.PubMedCrossRef
42.
Kalil, G. Z., & Haynes, W. G. (2012). Sympathetic nervous system in obesity-related hypertension: Mechanisms and clinical implications. Hypertension Research, 35(1), 4–16.PubMedCrossRef
43.
Astman, N., Friedberg, I., Wikstrom, J. D., Derazne, E., Pinhas-Hamiel, O., Afek, A., et al. (2019). The association between obesity and hyperhidrosis: A nationwide, cross-sectional study of 2.77 million Israeli adolescents. Journal of the American Academy of Dermatology, 81(2), 624–627.PubMedCrossRef
44.
45.
46.
Wade, R., Jones-Diette, J., Wright, K., Layton, A. M., & Woolacott, N. (2019). Hyperhidrosis quality of life measures: Review and patient perspective. Journal of Dermatological Treatment, 30(3), 303–308.CrossRefPubMed
Metagegevens
Titel
Comparison of EQ-5D-3L and metabolic components between patients with hyperhidrosis and the general population: a propensity score matching analysis
Auteurs
Yea-Chan Lee
Young Kyung You
Jun Hyuk Lee
Duk Hwan Moon
Sungsoo Lee
Soyoung Jeon
Hye Sun Lee
Ji-Won Lee
Publicatiedatum
11-05-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02856-8

Andere artikelen Uitgave 9/2021

Psychometric properties of the Dutch-Flemish PROMIS® pediatric item banks Anxiety and Depressive Symptoms in a general population

Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness

  • Open Access

Symptom profiles following combat injury and long-term quality of life: a latent class analysis

The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia

Association between knee symptoms, change in knee symptoms over 6–9 years, and SF-6D health state utility among middle-aged Australians

A psychometric evaluation of the Functional assessment of cancer therapy—kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure

  • Open Access